We show here that JNK1 activity is rapidly up-regulated and prolonged by specific mechanisms during apoptosis induced by paclitaxel-or ginsenoside-Rh2 in SK-HEP-1 cells. The early phase of JNK1 activation is prevented in cells expressing the dominant negative SEK1 mutant, although this JNK1 perturbation does not prevent apoptotic cell death. The later phase of JNK1 activation, which is temporally coincided with caspasedependent cleavage of JNK1-associated p21 WAF1/CIP1 , is efficiently prevented by expressing p21D112N, an uncleavable mutant of p21 WAF1/CIP1 and this perturbation of JNK1 activation results in prevention of apoptosis. The later JNK1 activation and apoptotic progression are also prevented by co-treatments of cells with rottlerin, a PKC-␦ inhibitor or z-VAD-fmk, a pan caspase inhibitor. We also provide evidence that apoptotic cell death is significantly promoted in cells expressing JNK1, while this apoptotic cell death is effectively suppressed in cells expressing the dominant negative JNK1 mutant (DN-JNK1) or JBD, a JNK inhibitor protein. Thus, the later phase of JNK1 activation, which is linked to a caspase-dependent mechanism that requires PKC-␦ activity, is associated with the induction of apoptosis, while the early JNK1 activation that is associated with a SEK1-mediated mechanism is not directly involved in apoptotic progression.
We show here that JNK1 activity is rapidly up-regulated and prolonged by specific mechanisms during apoptosis induced by paclitaxel-or ginsenoside-Rh2 in SK-HEP-1 cells. The early phase of JNK1 activation is prevented in cells expressing the dominant negative SEK1 mutant, although this JNK1 perturbation does not prevent apoptotic cell death. The later phase of JNK1 activation, which is temporally coincided with caspasedependent cleavage of JNK1-associated p21 WAF1/CIP1 , is efficiently prevented by expressing p21D112N, an uncleavable mutant of p21 WAF1/CIP1 and this perturbation of JNK1 activation results in prevention of apoptosis. The later JNK1 activation and apoptotic progression are also prevented by co-treatments of cells with rottlerin, a PKC-␦ inhibitor or z-VAD-fmk, a pan caspase inhibitor. We also provide evidence that apoptotic cell death is significantly promoted in cells expressing JNK1, while this apoptotic cell death is effectively suppressed in cells expressing the dominant negative JNK1 mutant (DN-JNK1) or JBD, a JNK inhibitor protein. Thus, the later phase of JNK1 activation, which is linked to a caspase-dependent mechanism that requires PKC-␦ activity, is associated with the induction of apoptosis, while the early JNK1 activation that is associated with a SEK1-mediated mechanism is not directly involved in apoptotic progression.
The c-Jun N-terminal kinase (JNK)
1 is a member of the family of mitogen-activated protein kinase (MAPK) that includes the ERK and p38 kinases (1) . Three genes encode the three JNK isoforms JNK1, JNK2, and JNK3 (2) . JNK3 mediates stress-induced neuronal apoptosis (3), while JNK1 and JNK2 have numerous roles in various cell lines (4) . It is widely believed that JNK plays an essential role in apoptosis induced by agents such as UV, cytokine, chemotherapeutic drugs, and ceramide (5, 6) . Recent studies with Jnk(Ϫ/Ϫ) knockout mice showed that JNK activity is required for excitotoxin-induced apoptosis in the adult hippocampus and for apoptosis in the developing embryonic neural tube (7) . Thus, JNK activity appears to be essentially involved in apoptotic progression of vaious cell types induced by a number of different apoptotic stimuli. JNK activity is regulated by various different mechanisms in cells under the different experimental conditions. JNK1 activity is differentially regulated by various different protein kinases including SEK1 (MKK4) and SEK2 (MKK7), upstream protein kinases of JNK (8) , PKC-␦ (9), apoptosis signal-regulating kinase 1 (ASK1) (10, 11) , mixed lineage kinases (MLKs) (12) , TGF-activated protein kinase 1 (TAK1) (13, 14) . PKC-␦ activity, an isozyme of PKC family is thought to be involved in JNK activation in response to ectoposide and UVB (15) . A recent study showed that dominant negative PKC-␦ or rottlerin, a PKC-␦-specific inhibitor, suppresses ionizing radiation-induced JNK activation in primary cultured human thyroid cells (9) . PKC-␦ activity is involved in activation process of caspase-3 during apoptosis (16) . JNK activity is also regulated by JNK-interacting protein (JIP). JIP competes with c-Jun, ATF2 and Elk for JNK binding via its JNK-binding domain (JBD) (17) . Recent results showed that the peptide sequence containing JBD prevents nuclear accumulation of phosphorylated c-Jun and also suppresses neuronal cell death induced by NGF deprivation (18) .
JNK1 activity is also regulated by the JNK1 inhibitor p21 WAF1/CIP1 , which dissociates from a complex with JNK1 upon the entry of T-lymphocytes and HeLa cells into S-phase (19, 20) . Caspase-3 cleaves p21 WAF1/CIP1 at a specific site in vitro; this same cleavage occurs in apoptosis of SK-HEP-1 cells treated with ginsenoside Rh2 (G-Rh2), a ginseng saponin with a dammarane skeleton isolated from the roots of Panax ginseng C. A. Meyer (21) . Previous reports have shown that caspasemediated cleavage permits the release of the cyclin/Cdk complex from the p21 WAF1/CIP1 inhibitor, resulting in an elevation of cyclin/Cdk kinase activity in the early stages of apoptosis (22) . The up-regulation of cyclin/Cdk kinase activity is required for apoptotic progression in several cell types, including HU-VEC cells, SK-HEP-1 cells, and HeLa cells (22, 23) . Therefore, we speculated that p21 WAF1/CIP1 plays a pivotal role in the induction of apoptosis.
In the present study, we thus, examined whether JNK1 activity is up-regulated as a consequence of proteolytic cleavage of p21 WAF1/CIP1 and whether this activation is a functionally relevant event in apoptotic cells induced by G-Rh2 or paclitaxel. Here we show that JNK1 activity is up-regulated by a mechanism that is associated with the SEK1 activity in ealier stages, but afterward by a different mechanism that involves proteolytic cleavage of JNK1 inhibitor p21 WAF1/CIP1 during apoptotic progression. We also provide evidence that JNK1 activity is efficiently down-regulated by ectopic overexpression of p21D112N, uncleavable mutant of p21 WAF1/CIP1 , and this down-regulation of JNK1 activity is functionally associated with suppression of apoptotic progression in the cells induced by treatment with G-Rh2 or paclitaxel. Further, we show that cells transiently expressing dominant negative version of JNK1 (DN-JNK1) or JBD, the JNK1 inhibitor, are markedly suppressed to undergo apoptosis induced by treatment of paclitaxel or G-Rh2. Thus, the JNK1 activation that is associated with PKC-␦ activity and also with proteolytic dissociation of p21 WAF1/CIP1 from JNK1-containing complexes, appears to be functionally relevant event in apoptotic progression of paclitaxel-and G-Rh2-induced cells.
EXPERIMENTAL PROCEDURES
Reagents-Gisenoside Rh2 (G-Rh2) was dissolved in 70% ethanol at a concentration of 10 mg/ml and stored at Ϫ20°C. Paclitaxel, rottlerin, and Go6976 were obtained from Calbiochem and were dissolved in Me 2 SO at a concentration of 100 M, 100 mM, and 50 mM, respectively, and stored at Ϫ20°C. GST-c-Jun and protein A-agarose beads were purchased from Upstate Biotechnology. The caspase-3 substrate N-acetyl-Asp-Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin (Ac-DEVD-AFC) was purchased from BD Pharmingen. [␥- 32 P]ATP and z-VAD-fmk were purchased from Sigma.
Cell Culture and Transfection-SK-HEP-1 and HeLa cells were maintained at 37°C in 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% calf serum and antibiotics-antimycotics (Invitrogen). SK-HEP-1 cells (1 ϫ 10 7 /cuvette) were transfected with 40 g of pCMV-p21D112N or pCMV-DN-SEK1, and co-transfected with 20 g each of pCMV-␤-gal and pcDNA3 (mock), pcDNA3-Flag-JNK1 (wild-type JNK1) or pcDNA3-Flag-DN-JNK1 (dominant negative JNK1) by means of electroporation (250 V and 1,200 F) employing the Bio-Rad Gene Pulser II, and 48 h later the cells were treated with G-Rh2 or paclitaxel. After X-gal staining of transfected cells, the shrunk/rounded blue cells among all blue cells were counted in twenty different comparable fields. HeLa cells grown on a 6-well plate (60% confluent) were co-transfected with 2 g each of pEGFP-C1 and pcDNA3 or pcDNA3-Flag-JBD using Polyfect (Qiagen) according to the manufacturer's instruction. 24 h after transfection, cells were treated with G-Rh2 or paclitaxel, and examined by fluorescence microscopy.
Western Blot Analysis-Western blots were performed according to standard methods. Cell pellets were lysed in lysis buffer (0.5% Triton X-100, 20 mM Tris-HCl, pH 7.5, 2 mM MgCl 2 , 1 mM dithiothreitol, 1 mM EGTA, 50 mM ␤ -glycerophosphate, 25 mM NaF, 1 mM Na 3 VO 4 , 2 g/ml leupeptin, 2 g/ml pepstatin A, 100 g/ml phenylmethylsulfonyl fluoride, 1 g/ml antipain) for 1 h. Lysates were subjected to SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (Gelman). The membrane was blocked with 5% non-fat dried milk (Carnation) in Tris-buffered saline (50 mM Tris-HCl, pH 7.5, 150 mM NaCl) containing 0.05% Tween 20 (TBS-T) and incubated in a 1:1000 dilution of mouse monoclonal anti-human caspase-3/CPP32 (Transduction Laboratories), mouse monoclonal anti-p21
, and rabbit polyclonal anti-JNK2 (Upstate Biotechnology), rabbit polyclonal antiphospho-MKK3/MKK6 and rabbit polyclonal anti-phospho-SEK1/ MKK4 (Cell Signaling Technology), mouse monoclonal anti-FLAG, and mouse monoclonal anti-␤-actin (Sigma), and mouse monoclonal antiphospho-c-Jun, mouse monoclonal anti-phospho-JNK1, rabbit polyclonal anti-JNK1, rabbit polyclonal anti-PARP, rabbit polyclonal antiphospho-p38, and rabbit polyclonal anti-phospho-ERK1 and 2 (Santa Cruz, CA). Bands were visualized with horseradish peroxidase-conjugated antibodies and the ECL system (Amersham Biosciences).
Immune Complex Kinase Assay-Cells were lysed with lysis buffer. The lysates were precleared by shaking with protein A-agarose beads (Upstate Biotechnology) for 1 h at 4°C and immunoprecipitated by shaking with rabbit polyclonal anti-JNK1 or JNK2 at 4°C. After an overnight incubation, immune complexes were recovered with protein A-agarose beads and washed three times with lysis buffer and three times with 20 mM HEPES (pH 7.4). Pellets were mixed with 1 g GST-c-Jun, 10 Ci [␥-32 P]ATP, 500 M unlabeled ATP, and kinase buffer containing 20 mM dithiothreitol, 100 mM MgCl 2 , and 2 mM Na 3 VO 4 . The kinase reaction was performed at 30°C for 30 min, and the supernatants were resolved by 12% SDS-PAGE. The proteins in the gel were stained with Coomassie Brilliant Blue R250. The gel was dried, and the phosphorylation of the c-Jun substrate was determined by autoradiography.
Immunoprecipitation-Samples of total protein (500 g) were incubated overnight at 4°C with rabbit polyclonal anti-JNK1, followed by incubation with protein A-agarose beads for 2 h. Immunoprecipitates were washed three times with lysis buffer and released from agarose beads by boiling in SDS sample buffer. The reaction mixture was resolved by 15% SDS-PAGE. After electrotransfer onto a polyvinylidene difluoride membrane, immunoprecipitates were analyzed by Western blotting as described above.
Caspase-3 Activity Assay-The caspase-3 substrate Ac-DEVD-AFC (BD Pharmingen) was used in caspase-3 assays according to a procedure based on the manufacturer's instructions. 20 g of cell lysates were added to the reaction buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM dithiothreitol, 0.1% CHAPS, 10% sucrose) containing 25 M of Ac-DEVD-AFC in a 96-well plate. Lysates were incubated at 37°C for 1 h. Fluorescence of the cleavage product was measured using a SpectraFluor F129003 (TECAN) at excitation and emission wavelengths of 405 and 465 nm, respectively.
Immunocytochemistry-Active caspase-3 staining was used to monitor apoptotic cell death. Cells were plated on 18 ϫ 18 mm glass coverslips at a confluency of 60% and were allowed to become adherent overnight. 24 h after co-transfection with 2 g each of pEGFP-C1 and pcDNA3 or pcDNA3-Flag-JBD, cells were either kept untreated or treated with G-Rh2. Cells were fixed with 4% paraformaldehyde at 37°C for 30 min and washed with phosphate-buffered saline. After incubation for 1 h with blocking solution containing 0.1% bovine serum albumin, 0.1% Triton X-100 and 2% CAS in phosphate-buffered saline at 4°C, cells were stained by incubating the coverslips for overnight with anti-active capsase-3 antibody (Promega). The active caspase-3 staining was revealed by incubating cells for 1 h with tetramethyl rhodamine isothiocyanate (TRITC)-conjugated goat anti-mouse IgG (Chemicon) and visualized by confocal microscopy (LEICA). Illumination sources were 488 nm and 505 nm.
RESULTS

JNK1 Activity Is Selectively and Progressively Up-Regulated Among MAPKs during Apoptotic Progression of SK-HEP-1
Cells-Here, we have addressed whether JNK1 activity is involved in apoptotic progression of SK-HEP-1 cells induced by treatment with G-Rh2. Kinase assays with the JNK1 immunocomplex showed that JNK1 activity increases in a progressive fashion, with an early activation beginning at 10 min after treatment of the cells with G-Rh2 and a later, more sustained, activation beginning at 60 min (Fig. 1B, lower panel) . By contrast, JNK2 activation and changes in its protein levels were not observed during G-Rh2-induced apoptosis. (Fig. 1B , two panels from bottom). The onset and time course for the later phase of JNK1 activation coincided well with the temporal profiles of caspase-3 activation, PARP cleavage, and morphological changes of cells with apoptotic characters (Fig. 1, A and B, upper and middle panels). JNK1 activation did not appear to be attributed to increased protein levels of the kinase (Fig. 1B) . In addition, JNK1 activation was specific, because the activities of other kinases including p38, ERK1, ERK2, and MKK3/ MKK6 as represented by levels of their phosphoforms were unchanged over the same time period (Fig. 1C) . The result also showed that the activity of SEK1 kinase, as represented by levels of phospho-SEK1/MKK4, increased in parallel with that of JNK1 over the first 30 min; however, thereafter the kinase activity was undetectable in G-Rh2-induced cells, while JNK1 activity continued (Fig. 1C) . We then examined whether a dominant negative version of SEK1 (DN-SEK1) can differentially perturb the JNK1 activation. The results showed that in cells transiently expressing DN-SEK1, the early JNK1 activation was effectively blocked, but was not the later JNK1 activation in G-Rh2-induced cells (Fig. 1D, upper panel) . Moreover, expression of DN-SEK1 did not significantly perturb the apoptotic progression, as indicated by the proteolytic cleavage of PARP in the cells (Fig. 1D, bottom panel) . SEK1 activity is thus, likely associated with the early phase of JNK1 activation but is independent of the later apoptosis-specific up-regulation of JNK1.
We next examined whether both early and later JNK1 activation are due to specific phosphorylation sites. The results showed that phosphorylation of JNK1 at Thr 183 /Tyr 185 was increased and paralleled with the time course of JNK1 activation during apoptosis, but the levels of phospho-JNK1 were not significantly changed during early and later JNK1 activation (Fig. 1B, the third panel from bottom) . The results indicated that both early and later JNK1 activation may not be due to phosphorylation at different locations.
Ectopic Expression of p21D112N, an Uncleavable Mutant of p21
WAF1/CIP1 Effectively and Equally Blocks the JNK1 Activation and Apoptotic Progression-We then examined whether proteolytic cleavage of p21 WAF1/CIP1 is associated with the later phase of JNK1 activation and also whether this JNK1 activity is involved in apoptotic progression of G-Rh2-induced cells, because proteolytic cleavage of p21 WAF1/CIP1 , an inhibitor protein of JNK1 occurred with a kinetics similar to the onset and time course for apoptosis in G-Rh2-induced SK-HEP-1 cells. The result from Western blot showed that the onset and time course for proteolytic cleavage of cellular p21 WAF1/CIP1 ( Fig. 2A , upper panel) coincides well with those of proteolytic dissociation of the JNK1-associated p21 WAF1/CIP1 in the cells ( Fig. 2A,  lower panel) . The later phase of JNK1 activation, thus, is likely associated with proteolytic dissociation of the JNK1 inhibitor from the JNK1 complex in the apoptotic cells. To provide evidence for this hypothesis, we tested whether ectopic overexpression of p21D112N, an uncleavable version of p21 WAF1/CIP1 , perturbs the later phase of JNK1 activation and apoptosis in G-Rh2-induced cells (Fig. 2B) . The results demonstrated that p21D112N being expressed at high levels in the transient transfectants (Fig. 2B, left panel) effectively suppresses both apoptotic progression as determined by proteolytic cleavage of PARP, and the later phase of JNK1 activation after 60 min of G-Rh2 treatment of the cells (Fig. 2B, upper and middle  panels) . Moreover, protein levels of the JNK1-associated p21 WAF1/CIP1 were correlated very well with the inhibitory effect on JNK1 activity in the cells (Fig. 2B, lower panel) . In the mock transfectants, JNK1 activity was markedly up-regulated in accordance with the time course for disappearance of p21 WAF1/CIP1 that is associated with JNK1-complex after 60 min of the G-Rh2 treatment. However, in the cells expressing p21D112N, later JNK1 activation was significantly suppressed after G-Rh2 treatment although early JNK1 activation was also slightly suppressed under the same conditions (Fig. 2B) . These results indicated that the later JNK1 activation is closely associated with proteolytic cleavage of the JNK1-associated p21 WAF1/CIP1 and this JNK1 activation is functionally relevant to the induction of apoptosis. To further provide evidence that the later JNK1 activation is attributed to proteolytic using GST-c-Jun (Upstate Biotechnology) as a substrate. The phosphorylated proteins were resolved by SDS-PAGE and visualized by autoradiography (the third and the sixth panel from top). Anti-JNK1 or anti-JNK2 immunoblotting of whole cell extracts recovered in each sample (the fourth and the first panel from bottom). The sites of phosphorylation of JNK1 were determined by Western blot analysis using specific antibody against p-JNK1 (Thr 183 /Tyr 185 ) (the third panel from bottom). C, kinase activities for other members of the MAPK family, including p38, ERK1 and 2, SEK1/MKK4, and MKK3/MKK6 were determined by Western blot analysis using antibodies that specifically recognize the phosphoform of the respective kinases, which represent the active form of these kinases. D, SK-HEP-1 cells were electroporated with a dominant negative version of SEK1 (pcDNA3-DN-SEK1 (Lys 3 Arg)) or the empty vector (pcDNA3). Levels of expression of SEK1 and JNK1 proteins were determined by Western blot analysis using specific antibodies. Time courses for JNK1 activation and apoptotic progression in G-Rh2-induced cells were determined by Western blot analysis using an anti-phospho-c-Jun or anti-PARP antibody, respectively. Two independent experiments were performed. A, SK-HEP-1 cells treated with G-Rh2 (7.5 g/ml) for the indicated times were photographed under phase contrast microscope (100ϫ). The arrow indicates the apoptoic cell. B, cells treated for the indicated times with G-Rh2 (7.5 g/ml) were harvested, lysed, and analyzed by SDS-PAGE. Western blot analysis was carried out using antibodies against either caspase-3 (Transduction Laboratories) or PARP (Santa Cruz Biotechnology). JNK1 or JNK2 kinase activity was determined by immune complex kinase assay. Briefly, cell lysates were immunoprecipitated with anti-JNK1 (Santa Cruz Biotechnology) or anti-JNK2 (Upstate Biotechnology), and immunoprecipitates were subjected to kinase assay cleavage of the JNK1-associated p21
WAF1/CIP1 , we tested whether z-VAD-fmk, a broad caspase inhibitor, could suppress the later phase of JNK1 activation and the apoptotic progression of G-Rh2-induced cells, because the site-specific cleavage of p21 WAF1/CIP1 in apoptosis is mediated by a caspase-3-like protease. As expected, both events were consequently blocked, as shown by the failure of PARP to undergo cleavage and by the decreased levels of p-c-Jun, respectively (Fig. 2C, upper and  middle panels) . Thus, the later phase of JNK1 activation is tightly linked to an activation mechanism that requires caspase activity and this kinase activity is again functionally associated with apoptosis. Since the protein levels of JNK1 were not changed in the cells following treatment with either G-Rh2 or z-VAD-fmk, or both, (Fig. 2C, lower panel) , we ruled out the possibility that the suppressive effect on JNK1 activity is due to proteolytic degradation of JNK1 protein.
The Later JNK1 Activation Is Linked to PKC-␦ Activation in Apoptotic Progression-An earlier report has shown that PKC-␦ is involved in the activation of JNK1 in apoptosis of UVB-treated cells (15) . We then investigated if PKC-␦ activity is also involved in the later apoptosis-specific JNK1 activation. For this, we first examined if PKC-␦ activity is functionally associated with the later phase of JNK1 activation. The results clearly showed that the later JNK1 activations, as determined by levels of phosphoform of JNK1 (p-JNK1), are efficiently blocked by cotreatment of the cells with rottlerin, a specific PKC-␦ inhibitor (Fig. 3A) . Moreover, this inhibitor accordingly blocked the G-Rh2-induced apoptosis to the control levels, as determined by proteolytic cleavages of procaspase-3 and PARP (Fig. 3B) . In addition, rottlerin prevented G-Rh2-induced activation of caspase-3 as measured by cleavage of Ac-DEVD-AFC, while the conventional PKC inhibitor, Go6976 did not (Fig. 3C) . Thus, PKC-␦ activity is very likely linked to the activation of caspase-3. These results indicated that PKC-␦ activity-dependent caspase-3 activity is involved in the later phase of JNK1 activation in G-Rh2-induced apoptosis.
JNK1 Activity Is Required in Apoptotic Progression-To provide direct evidence that the later phase of JNK1 activation is essential for the induction of apoptosis, we tested whether ectopic expression of dominant negative version of JNK1 (DN-
FIG. 2. Ectopic expression of p21D112N equally inhibits the activation of JNK1 and apoptotsis. A, proteolytic cleavage of p21 WAF1/CIP1
was analyzed by immunoblotting using a specific anti-p21 WAF1/CIP1 antibody (upper panel). To determine protein level of p21 WAF1/CIP1 that is associated with JNK1, 500 g of cell lysates were immunoprecipitated with anti-JNK1 for overnight. Immune complexes were recovered with protein A-agarose beads, subjected to 15% SDS-PAGE, and analyzed by immunoblotting for p21 WAF1/CIP1 (lower panel). B, 48 h after electroporation (250 V and 1,200 F, Bio-Rad Gene Pulser II), the ectopic expression of p21D112N (40 g, pCMVp21D112N) in transfectants, proteolytic cleavages of PARP or JNK1 activity in a time-dependent manner was determined by Western blot analysis using p21
, PARP or p-c-Jun (left, upper and middle panels). The amounts of p21 WAF1/CIP1 associated with JNK1 in transfectants were determined by immunoblotting of the immunoprecipitated complexes using an anti-JNK1 antibody (lower panel). C, SK-HEP-1 cells were pretreated for 2 h with increasing doses of z-VAD-fmk. JNK1 activity and proteolytic cleavage of PARP were determined after treatment of cells with G-Rh2 as described in B. Levels of JNK1 and ␤-actin were also determined in parallel by Western blot analysis.
FIG. 3. Rottlerin, a PKC-␦ inhibitor, effectively suppresses JNK1 activation and apoptosis equally well.
A, SK-HEP-1 cells were treated with G-Rh2 (7.5 g/ml) for 1 or 2 h in the presence or absence of rottlerin. JNK1 activity and protein levels were determined by Western blot analysis using anti-phospho-JNK1 or anti-JNK1 antibodies, respectively. B, time course of proteolytic caspase-3 activation and PARP cleavage was determined by Western blot analysis using anti-caspase-3 and anti-PARP antibodies, respectively. C, G-Rh2-induced activity of caspase-3 was determined using the synthetic peptide substrate, Ac-DEVD-AFC. Rottlerin with co-treatment of G-Rh2 inhibited activation of caspase-3, while Go6976 (100 nM 
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JNK1) or JBD can differentially perturb apoptotic progression by selectively blocking JNK1 activity in SK-HEP-1 and HeLa cells treated with G-Rh2 or paclitaxel. Since the transfection efficiency of SK-HEP-1 cells with the DNA constructs was relatively low, we co-transfected the cells with the pcDNA3 vector carrying the ␤-gal cDNA to mark transfected cells. After X-gal staining on transfected cells, blue stained cells were counted and evaluated for their effects on apoptosis of the transfectants after treatment with G-Rh2 or paclitaxel (Fig. 4,  A and C) . The results clearly showed that apoptotic cell death is significantly promoted by transiently expressing the wildtype JNK1, while it is effectively suppressed by expressing DN-JNK1 in cells treated with G-Rh2 (Fig. 4A) or paclitaxel  (Fig. 4C) . Similarly, apoptotic cell death was significantly suppressed in HeLa cells expressing JBD after treatment with G-Rh2 or paclitaxel (Fig. 4, B and D) Further, the cell populations with apoptotic morphology such as condensed chromatin and shrinkage of cell size were markedly reduced in cells coexpressing JBD and GFP proteins as compared with those of mock transfectants following treatment of cells with G-Rh2 or paclitaxel. (Fig. 4E) . To substantiate these results, we also determined apoptosis by staining active caspase-3 of these transfectants. The results showed that cell populations with active caspase-3 were significantly suppressed in transfectants co-expressing JBD and GFP proteins following treatment of cells with G-Rh2, while those with active caspase-3 were markedly increased in mock transfectants co-expressing GFP protein under the same conditions (Fig. 4F) . These results clearly indicate that JNK1 activation is functionally relevant event to promote the apoptotic progression of the G-Rh2-or paclitaxelinduced cells.
DISCUSSION
Prolonged JNK1 Activations during Apoptosis Are Regulated
by Specific Activation Mechanisms-The data we provide in this study show that JNK1 activation is required for apoptosis induced by two different agents, G-Rh2 or paclitaxel in human hepatoma SK-HEP-1 and HeLa cells. JNK1 activation during apoptosis shows a rapid and prolonged up-regulation profile in that the early activation is evidently detectable as early as 10 min and the later activation is not only higher than the first one, but also coincident very well with the onset and time course of apoptosis that occurs after 1 h of the treatment (Fig.  1B) . JNK1 activation appears to be specific because the activities of other protein kinases including JNK2 are remained unaltered during apoptosis (Fig. 1, B and C) . Interestingly, the later JNK1 activation appears to be mechanistically unrelated to the earlier JNK1 activation. The reason is that the SEK1 activity in the cells increases in parallel with the JNK1 activity only for the first 30 min, but thereafter is undetectable in the G-Rh2-induced cells, while the JNK1 activity keeps on gradually increasing during apoptotic progression. It is interesting to note here that both early and later JNK1 activation are unlikely due to increased phosphorylation of JNK1 at positions, Thr 183 and Tyr 185 , phosphorylation of which residues are essential for JNK1 activation. Our results show that the levels of phospho-JNK1 (Thr 183 /Tyr 185 ) are not significantly changed during early and later JNK1 activation (Fig. 1B) . Importantly, in the transfection study with DN-SEK1, a dominant negative version of SEK1, overexpression of DN-SEK1 efficiently perturbs the early phase of JNK1 activation, but does not perturb the later phase of JNK1 activation in apoptotic cells (Fig. 1D) . Thus, the results suggest that the early phase of JNK1 activation is linked to the SEK1-mediated mechanism, while the later phase of JK1 activation is conducted by a different mechanism.
The Later Phase of JNK1 Activation Requires Proteolytic Cleavage of p21 WAF1/CIP1 That Is Associated with the JNK1 Complex-Since the later phase of JNK1 activation is not related to SEK1 activity in apoptotic progression of G-Rh2-induced cells (Fig. 3) , we examined whether the later phase of JNK1 activation is associated with proteolytic cleavage of p21 WAF1/CIP1 , because of the following reasons. First, p21 WAF1/CIP1 has been shown as an inhibitor of JNK1 in vitro as well as in the cell culture. And thus, proteolytic dissociation of the inhibitor protein from JNK1 complex would consequently result in up-regulation of the kinase activity (20) . Second, it has been also shown that proteolytic cleavage of this inhibitor is functionally relevant event for the induction of apoptosis (22) . Our findings show that the JNK1-associated p21 WAF1/CIP1 is proteolytically dissociated from the JNK1 complex with the same onset and time courses for proteolytic cleavage of cellular p21 WAF1/CIP1 and the later JNK1 activations in G-Rh2-induced apoptotic cells ( Fig. 2A) . Importantly, p21D112N efficiently suppresses the later phase of JNK1 activation and G-Rh2-induced apoptosis (Fig. 2B) . The functional implication of proteolytic cleavage of p21 WAF1/CIP1 is also supported by that protein levels of p21 WAF1/CIP1 associated with the JNK1 complex are correlated well with the suppression of JNK1 activity (Fig.  2B) . The results thus, suggest that the rapid and prolonged JNK1 activations during apoptosis are conducted by two specific mechanisms, the SEK1-mediated mechanism and an activation mechanism that is related to proteolytic dissociation of the inhibitor protein from JNK1-containing complex. In earlier studies, biphasic activations of JNK1 during apoptotic progression have been observed with other cell types induced by different apoptosis inducers including tumor necrosis factor ␣ (TNF␣) in a fibroblast cell line that stably expresses a fusion of murine DC4 and Fas (24), 12-0-tetradecanoulphorbol 13-acetate (TPA) in the androgen-responsive prostate cancer cell line LNCaP (25) . It has been postulated in these reports that either the early increase in JNK activity contributes to the later, sustained increase in JNK activity, which in turn plays a role in the induction of apoptosis or alternatively, the early JNK activation could be mechanistically and causally unrelated to the later phase of JNK activation (25) . Here, we show that the early JNK1 activation is functionally associated with the upstream kinase SEK1 activity, whereas the later phase of JNK1 activation is mechanistically and causally unrelated to the early JNK1 activation.
The Later JNK1 Activation Is Linked to PKC-␦ Activity-dependent Caspase Activity during Apoptotic Progression-For the following reasons, we have addressed here whether the later phase of JNK1 activation, which is unrelated to the SEK1-mediated mechanism, requires PKC-␦ activity. First, the SEK1-mediated JNK1 activation is limited only to the early stage of apoptosis (Fig. 1C) . Second, PKC-␦ activity is thought to be linked to JNK1 activity in the cells induced by treatment with etoposide or UVB (15) . Our data show that rottlerin effecanalysis using a monoclonal anti-FLAG antibody (B and D). E, transfected cells were identified by fluorescence microscopy (100ϫ). Arrowheads indicate the apoptotic morphology showing condensed GFP-positive cells and the arrows indicate the normal GFP-positive cells. F, apoptosis of transfected cells was also determined by staining active caspase-3. Transfectants co-expressing GFP and mock or JBD were treated with G-Rh2 (6 g/ml) for 6 h and then monitored by a confocal microscopy after staining cells using anti-active caspase-3 antibody and anti-mouse antibody conjugated to tetramethyl rhodamine isothiocyanate (TRITC) as described under "Experimental Procedures." Cells with active caspase-3-positive show red staining.
tively and equally suppresses the later phase of JNK1 activation and apoptosis as indicated by suppressed levels of proteolytic cleavages of procaspase-3 and PARP of the G-Rh2-induced cells (Fig. 3) . These results are consistent with the notion that the later phase of JNK1 activation is attributed to proteolytic dissociation of the JNK1 inhibitor protein. The reason is that rottlerin, which can selectively block the PKC-␦ activity-dependent caspase-3 activation is able to prevent caspase-3-activity-dependent JNK1 activation that is attributed to caspase-3-mediated dissociation of the JNK1 inhibitor protein in G-Rh2-induced cells. Our results are also supporting for those of previous studies. Previously, PKC-␦ has been shown to be required for mitochondria-dependent apoptosis (26) . The nuclear import of PKC-␦ is also required in apoptosis (27) and that nuclear PKC-␦ plays an important role in mediating upregulation of caspase-3 activity in Jurkat T leukemic cells exposed to ionizing radiation (16) . An earlier study has also shown that the phosphorylation of p21 WAF1/CIP1 at Ser 146 by PKC modulates its ability to interact with PCNA (28) . Thus, there is a possibility that PKC-␦ may also be involved in up-regulation of the later phase of JNK1 activation that is functionally linked to caspase-dependent dissociation of p21 WAF1/CIP1 , JNK1 inhibitor protein, during apoptotic progression.
Results herein imply that the early JNK1 activation is not functionally associated with the induction of apoptosis because, as evidenced by the results from the PARP cleavage assays (Fig. 1D) , in cells expressing DN-SEK1, the early JNK1 activation is effectively prevented, but the PARP cleavages are not significantly perturbed during apoptosis in G-Rh2-induced cells. Although it is not clear how JNK1 is functionally and mechanistically linked to apoptosis, JNK activity appears to be involved in dual roles in signaling pathways for cell survival and apoptosis in different cell types induced by different stimuli. Some reports have concluded that JNK activity is required for cell survival of various cell types (29, 30) , while other studies have suggest that JNK activity is required for apoptosis of different cell types (25, 31) . Such discrepancies in the published literature have been reasoned to be due, at least in part, to specific cell type differences (32) . However, in murine IL-3-dependent FDC-P1 cells stably expressing DN-JNK1, DN-JNK1 potently blocks IL-3 withdrawal-or anisomycin-induced Bcl-2 phosphorylation and also enhances the rate of cell death following IL-3 withdrawal or anisomycin treatment (32) . Further, in SEK1 gene-deficient mice, primary activated peripheral T cells exhibit enhanced susceptibility to apoptosis in response to TCR/CD⑀ religation (33) . Therefore, there is a possibility that the SEK1-dependent JNK1 activation, such as the early JNK1 activation in G-Rh2-induced cells is functionally relevant event to the protection of cell survival against apoptotic cell death before the induced cells commit to apoptotic progression.
The Later Phase of JNK1 Activation Is Essential for the Induction of Apoptosis-Since overexpression of p21D112N inhibits the later phase of JNK1 activation and G-Rh2-induced apoptosis (Fig. 2B) , we investigated whether the later JNK1 activation is required for the induction of apoptosis. The results from studies with transfectants show that JNK1 significantly enhances, but DN-JNK1 markedly suppresses the susceptibility of the cells to G-Rh2-or paclitaxel-induced apoptosis in SK-HEP-1 cells (Fig. 4, A and C) . Further, in cells expressing JBD, apoptosis as represented by percentage of cell viability is markedly suppressed after treatment with G-Rh2 or paclitaxel (Fig. 4, B and D) . The results evidently suggest that the later activated JNK1 is involved in the induction of apoptosis. The result is consistent with the results of earlier studies. In Jnk(Ϫ/Ϫ) knockout mice, experiments have provided evidence that JNK activity may be required for excitotoxininduced apoptosis in the adult hippocampus and for apoptosis in the developing embryonic neural tube (7) . Direct inhibition of JNK activity in sympathetic neurons by treatment with the compound SB 203580, JNK inhibitor or by expressing the JBD of JIP-1 is shown to prevent NGF-induced apoptotic death (34) .
Collectively, we suggest that the early activation of JNK1 may be associated with a protective role for cell survival until the induced cells commit to apoptosis, whereas the later activation is linked to execution of apoptotic progression. On the basis of these results, we propose a possibility that the rapid and prolonged JNK1 activation, which are conducted by specific mechanisms, are functionally associated with an important role as a checkpoint for the execution of apoptosis.
